Revenue Growth

Your own ranges are part of Powerpack. Powerpack

EPS Growth (diluted)

Your own ranges are part of Powerpack. Powerpack

Net Income Growth

Your own ranges are part of Powerpack. Powerpack

Operating Income Growth

Your own ranges are part of Powerpack. Powerpack

Gross Profit Growth

Your own ranges are part of Powerpack. Powerpack

Free Cash Flow Growth

Your own ranges are part of Powerpack. Powerpack

Operating Cash Flow Growth

Your own ranges are part of Powerpack. Powerpack

3Y Reveue CAGR

Your own ranges are part of Powerpack. Powerpack

5Y Revenue CAGR

Your own ranges are part of Powerpack. Powerpack

10Y Revenue CAGR

Your own ranges are part of Powerpack. Powerpack

5Y Net Income CAGR

Your own ranges are part of Powerpack. Powerpack

5Y OCF CAGR

Your own ranges are part of Powerpack. Powerpack

Book Value per Share Growth

Your own ranges are part of Powerpack. Powerpack

Next Y EPS Growth

Your own ranges are part of Powerpack. Powerpack

Next 5Y EPS Growth

Your own ranges are part of Powerpack. Powerpack

Forward Revenue (1y)

Your own ranges are part of Powerpack. Powerpack

Revenue vs Own Guidance

Your own ranges are part of Powerpack. Powerpack

Revenue Guidance Change

Your own ranges are part of Powerpack. Powerpack

Showing the 10 largest of 35 matches.
1 filter active
  1. Moderna, Inc.

    MRNA Healthcare · Biotechnology · US

    $223.37 +792.7% 1Y
    Low $22.28 High $280.80

    Moderna is a biotechnology company based in Cambridge, led by chief executive Stéphane Bancel. It develops medicines using messenger RNA, or mRNA: instructions that direct the body’s cells to make proteins.

    Market cap $93.6B
    Revenue growth (Q) +29.2%
    EPS growth (Q) +174.5%
    FCF growth (Q) −90.9%
    Revenue growth (next yr) +24.0%
    Net margin −110.5%
    ROE −34.5%
    P/E —
    Forward P/E −30.3×
    P/FCF —
    Dividend yield —
    Insider ownership 7.70%
    Insider buys / sells (12M) — $81.6M
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $19.3B $6.8B $3.2B $1.9B $2.5B
    EPS $20.12 −$12.33 −$9.28 −$7.26 −$7.10
    Free cash flow $4.6B −$3.8B −$4.1B −$2.1B −$2.0B
    Net debt −$9.0B −$8.0B −$7.0B −$5.2B −$1.6B

    This screen

    Red Flag This Week Now Yes
  2. Devon Energy Corporation

    DVN Energy · Oil & Gas E&P · US

    $46.58 +32.9% 1Y
    Low $34.23 High $52.71

    Devon Energy is an independent energy company that explores for, develops and produces crude oil, natural gas and natural-gas liquids (NGLs). In plain terms, it leases or owns interests in oil-and-gas acreage, drills and completes wells, operates many of those wells, and sells the hydrocarbons they produce.

    Market cap $52.7B
    Revenue growth (Q) +58.4%
    EPS growth (Q) −19.3%
    FCF growth (Q) +55.8%
    Revenue growth (next yr) +50.1%
    Net margin 16.2%
    ROE 12.6%
    P/E 11.6×
    Forward P/E 9.1×
    P/FCF 26.9×
    Dividend yield 2.41%
    Insider ownership 1.93%
    Insider buys / sells (12M) $0.2M $5.6M
    EPS v consensus Q to Sep 2026 Beat by $0.18 (adjusted $1.42 v $1.24)
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $19.2B $15.3B $15.9B $17.2B $22.2B
    EPS $9.12 $5.84 $4.56 $4.17 $4.00
    Free cash flow $3.4B $2.6B −$829.0M $3.3B $2.0B
    Net debt $5.0B $5.3B $8.0B $7.0B $10.2B

    This screen

    Red Flag This Week Now Yes
  3. Vylor Inc.

    VYLR Financial · Shell Companies · US

    $72.54 0.00% 1Y
    Low $65.00 High $77.39
    Market cap $48.1B
    Revenue growth (Q) —
    EPS growth (Q) —
    FCF growth (Q) —
    Revenue growth (next yr) —
    Net margin —
    ROE —
    P/E —
    Forward P/E —
    P/FCF —
    Dividend yield 0.00%
    Insider ownership —
    Insider buys / sells (12M) — —
    EPS v consensus Q to Sep 2026 Beat by $0.02 (adjusted −$0.42 v −$0.44)
    Reported TTM
    Net debt $4.3B

    This screen

    Red Flag This Week Now Yes
  4. Waters Corporation

    WAT Healthcare · Diagnostics & Research · US

    $460.25 +21.4% 1Y
    Low $282.77 High $483.33

    Waters Corporation makes laboratory instruments, software and supplies used to analyze materials and biological samples. Its customers include drug developers, clinical laboratories, industrial companies, universities and government agencies.

    Market cap $45.4B
    Revenue growth (Q) +120.9%
    EPS growth (Q) −67.2%
    FCF growth (Q) −66.7%
    Revenue growth (next yr) +105.1%
    Net margin 1.76%
    ROE 1.12%
    P/E 196×
    Forward P/E 133×
    P/FCF 174×
    Dividend yield —
    Insider ownership 0.00%
    Insider buys / sells (12M) $0.5M $1.4M
    EPS v consensus Q to Sep 2026 Beat by $0.11 (adjusted $4.10 v $3.99)
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $3.0B $3.0B $3.0B $3.2B $5.6B
    EPS $11.73 $10.84 $10.71 $10.76 $2.33
    Free cash flow $428.2M −$840.2M $619.6M $507.6M $258.6M
    Net debt $1.0B $1.9B $1.3B $359.6M $3.9B

    This screen

    Red Flag This Week Now Yes
  5. Rocket Lab Corporation

    RKLB Industrials · Aerospace & Defense · US

    $61.53 +36.4% 1Y
    Low $37.57 High $151.00

    Rocket Lab designs rockets and spacecraft, launches satellites and supplies equipment and services used in space. Its customers include government agencies, commercial spacecraft operators and other aerospace companies.

    Market cap $40.5B
    Revenue growth (Q) +72.7%
    EPS growth (Q) −307.3%
    FCF growth (Q) +65.4%
    Revenue growth (next yr) +62.9%
    Net margin −25.7%
    ROE −6.41%
    P/E —
    Forward P/E −200×
    P/FCF —
    Dividend yield —
    Insider ownership 4.58%
    Insider buys / sells (12M) — $691.3M
    EPS v consensus Q to Sep 2026 Missed by $0.05 (adjusted −$0.07 v −$0.02)
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $211.0M $244.6M $436.2M $601.8M $881.9M
    EPS −$0.29 −$0.38 −$0.38 −$0.37 −$0.36
    Free cash flow −$149.0M −$149.9M −$103.4M −$321.4M −$324.9M
    Net debt −$353.3M −$124.2M −$2.5M −$847.8M −$4.6B

    This screen

    Red Flag This Week Now Yes